Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1

Phase 3

Not yet recruiting

Conditions: AML
RUNX1-RUNX1T1 Fusion Protein Expression

Interventions: Drug: cytarabine
Drug: daunorubicin
Drug: idarubicin
Drug: cyclophosphamide

First Posted Date: 2024-12-20

Last Posted Date: 2024-12-20

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 300

Registration Number: NCT06744504

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Phase 2

Not yet recruiting

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
T Acute Lymphoblastic Leukemia

Interventions: Drug: Asparaginase Erwinia chrysanthemi
Procedure: Biospecimen Collection
Procedure: Bone Marrow Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Etoposide
Biological: Filgrastim
Biological: Pegfilgrastim
Procedure: Positron Emission Tomography
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine

First Posted Date: 2024-12-17

Last Posted Date: 2024-12-17

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT06738368

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Participants With Immune-Mediated Diseases (Ntrust-2)

Phase 1

Recruiting

Conditions: Systemic Sclerosis
Idiopathic Inflammatory Myopathies
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions: Drug: NKX019
Drug: Cyclophosphamide

First Posted Date: 2024-12-13

Last Posted Date: 2024-12-13

Lead Sponsor: Nkarta, Inc.

Target Recruit Count: 90

Registration Number: NCT06733935

Locations: 🇺🇸
HMH Hackensack University Medical Center, Hackensack, New Jersey, United States

Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in Patients with Secondary CNS Lymphoma

Phase 1

Not yet recruiting

Conditions: CNS Lymphoma

Interventions: Drug: Zanubrutinib
Drug: Methotrexate
Drug: Polatuzumab Vedotin
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: University of Miami

Target Recruit Count: 20

Registration Number: NCT06730542

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Treatment of Moderate to Severe Refractory Crohn's Disease

Phase 1

Not yet recruiting

Conditions: Crohns Disease

Interventions: Biological: TRX103
Drug: Cyclophosphamide

First Posted Date: 2024-12-06

Last Posted Date: 2024-12-06

Lead Sponsor: Tr1X, Inc.

Target Recruit Count: 22

Registration Number: NCT06721962

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States

and more 2 locations